• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry

tetano

Editor, Senior Moderator
Viruses. 2019 Feb 20;11(2). pii: E176. doi: 10.3390/v11020176.
[h=1]Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry.[/h] Mazzon M[SUP]1[/SUP], Ortega-Prieto AM[SUP]2[/SUP], Imrie D[SUP]3[/SUP], Luft C[SUP]4[/SUP], Hess L[SUP]5[/SUP], Czieso S[SUP]6[/SUP], Grove J[SUP]7[/SUP], Skelton JK[SUP]8[/SUP], Farleigh L[SUP]9[/SUP], Bugert JJ[SUP]10,[/SUP][SUP]11[/SUP], Wright E[SUP]12[/SUP], Temperton N[SUP]13[/SUP], Angell R[SUP]14[/SUP], Oxenford S[SUP]15[/SUP], Jacobs M[SUP]16[/SUP], Ketteler R[SUP]17[/SUP], Dorner M[SUP]18[/SUP], Marsh M[SUP]19[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Viruses are a major threat to human health and economic well-being. In recent years Ebola, Zika, influenza, and chikungunya virus epidemics have raised awareness that infections can spread rapidly before vaccines or specific antagonists can be made available. Broad-spectrum antivirals are drugs with the potential to inhibit infection by viruses from different groups or families, which may be deployed during outbreaks when specific diagnostics, vaccines or directly acting antivirals are not available. While pathogen-directed approaches are generally effective against a few closely related viruses, targeting cellular pathways used by multiple viral agents can have broad-spectrum efficacy. Virus entry, particularly clathrin-mediated endocytosis, constitutes an attractive target as it is used by many viruses. Using a phenotypic screening strategy where the inhibitory activity of small molecules was sequentially tested against different viruses, we identified 12 compounds with broad-spectrum activity, and found a subset blocking viral internalisation and/or fusion. Importantly, we show that compounds identified with this approach can reduce viral replication in a mouse model of Zika infection. This work provides proof of concept that it is possible to identify broad-spectrum inhibitors by iterative phenotypic screenings, and that inhibition of host-pathways critical for viral life cycles can be an effective antiviral strategy.


[h=4]KEYWORDS:[/h] Semliki Forest virus; Zika; alphaviruses; broad-spectrum antivirals; dengue; endocytosis; flaviviruses; host-targeted antivirals; phenotypic screening; virus entry

PMID: 30791609 DOI: 10.3390/v11020176
Free full text
 
Back
Top Bottom